Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Oncol Pract ; 14(6): e375-e383, 2018 06.
Article in English | MEDLINE | ID: mdl-28981388

ABSTRACT

PURPOSE: The Oncology Care Model (OCM) is a highly controversial specialty care model developed by the Centers for Medicare & Medicaid aimed to provide higher-quality care at lower cost. Because oncologists will be increasingly held accountable for spending as well as quality within new value-based health care models like the OCM, they need to understand the drivers of total spending for their patients. METHODS: This retrospective cohort study included patients ≥ 65 years of age with primary fee-for-service Medicare insurance who received antineoplastic therapy at 12 cancer centers in the Southeast from 2012 to 2014. Medicare administrative claims data were used to identify health care spending during the prechemotherapy period (from cancer diagnosis to antineoplastic therapy initiation) and during the OCM episodes of care triggered by antineoplastic treatment. Total health care spending per episode includes all types of services received by a patient, including nononcology services. Spending was further characterized by type of service. RESULTS: Average total health care spending in the three OCM episodes of care was $33,838 (n = 3,427), $23,811 (n = 1,207), and $19,241 (n = 678). Antineoplastic drugs accounted for 27%, 32%, and 36% of total health care spending in the first, second, and third episodes. Ten drugs, used by 31% of patients, contributed 61% to drug spending ($18.8 million) in the first episode. Inpatient spending also substantially contributed to total costs, representing 17% to 20% ($30.5 million) of total health care spending. CONCLUSION: Health care spending was heavily driven by both antineoplastic drugs and hospital use. Oncologists' ability to affect these types of spending will determine their success under alternative payment models.


Subject(s)
Health Expenditures , Insurance, Health , Neoplasms/epidemiology , Age Factors , Aged , Aged, 80 and over , Comorbidity , Delivery of Health Care/economics , Drug Costs , Female , Health Care Costs , Humans , Male , Medical Oncology/economics , Medicare/economics , Neoplasms/diagnosis , Neoplasms/therapy , Quality of Health Care , Retrospective Studies , United States
2.
Obstet Gynecol ; 102(3): 521-3, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12962935

ABSTRACT

BACKGROUND: Postmenopausal uterine inversion is an extremely rare gynecologic complication. We report a case of uterine inversion associated with endometrial polyps alone. CASE: A postmenopausal nullipara with a history of recurrent postmenopausal bleeding was evaluated for persistent vaginal bleeding. Benign endometrial polyps were found, and the patient's symptoms improved after a therapeutic dilation and curettage. She had acute onset of profuse vaginal bleeding 3 months later and a mass protruded from the cervix. A laparotomy revealed an inverted uterus that was resolved by the Haultain technique and was followed by total abdominal hysterectomy. CONCLUSION: Nonpuerperal uterine inversion associated with endometrial polyps was successfully treated surgically.


Subject(s)
Endometrial Neoplasms/diagnosis , Hysterectomy/methods , Polyps/diagnosis , Uterine Inversion/diagnosis , Endometrial Neoplasms/complications , Endometrial Neoplasms/surgery , Female , Follow-Up Studies , Humans , Laparotomy/methods , Middle Aged , Polyps/complications , Polyps/surgery , Postmenopause , Rare Diseases , Risk Assessment , Severity of Illness Index , Treatment Outcome , Uterine Hemorrhage/etiology , Uterine Hemorrhage/surgery , Uterine Inversion/complications , Uterine Inversion/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...